{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:05:31Z","timestamp":1782140731939,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T00:00:00Z","timestamp":1460592000000},"content-version":"vor","delay-in-days":530,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ihj.2013.12.021","type":"journal-article","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:45:13Z","timestamp":1389055513000},"page":"640-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Dofetilide induced torsade de pointes: Mechanism, risk factors and management strategies"],"prefix":"10.1016","volume":"66","author":[{"given":"Abhishek","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Goldbarg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2013.12.021_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ihj.2013.12.021_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0002-9149(92)90996-C","article-title":"Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris","volume":"69","author":"Sedgwick","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14779072.5.1.9","article-title":"Dofetilide: a new class III antiarrhythmic agent","volume":"5","author":"Roukoz","year":"2007","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ihj.2013.12.021_bib4","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(00)03402-4","article-title":"Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial","volume":"356","author":"Kober","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.021_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1074248407299272","article-title":"Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function","volume":"12","author":"Mykytsey","year":"2007","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ihj.2013.12.021_bib6","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.ijcard.2007.04.014","article-title":"Late dofetilide-associated life-threatening proarrhythmia","volume":"127","author":"Kolb","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib7","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.ehj.2004.08.020","article-title":"Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome","volume":"25","author":"Noda","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2013.12.021_bib8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1540-8159.1998.tb00148.x","article-title":"Taking the \u201cidio\u201d out of \u201cidiosyncratic\u201d: predicting torsades de pointes","volume":"21","author":"Roden","year":"1998","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib9","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1161\/01.CIR.90.5.2534","article-title":"Sudden cardiac death in heart failure. The role of abnormal repolarization","volume":"90","author":"Tomaselli","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.021_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1113\/jphysiol.2002.024570","article-title":"Cytosolic Ca2+ triggers early after depolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome","volume":"543","author":"Choi","year":"2002","journal-title":"J Physiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/pr.110.003723","article-title":"Drug-induced long QT syndrome","volume":"62","author":"Kannankeril","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ihj.2013.12.021_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/med.20019","article-title":"QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development","volume":"25","author":"Recanatini","year":"2005","journal-title":"Med Res Rev"},{"key":"10.1016\/j.ihj.2013.12.021_bib13","first-page":"233","article-title":"Electrolyte disorders and arrhythmogenesis","volume":"18","author":"El-Sherif","year":"2011","journal-title":"Cardiol J"},{"key":"10.1016\/j.ihj.2013.12.021_bib14","doi-asserted-by":"crossref","first-page":"39D","DOI":"10.1016\/S0002-9149(02)03378-7","article-title":"Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues","volume":"91","author":"Wolbrette","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"55","author":"Drew","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jacc.2004.09.069","article-title":"Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil","volume":"45","author":"Aiba","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2174\/157340309788970397","article-title":"Iatrogenic QT abnormalities and fatal arrhythmias: mechanisms and clinical significance","volume":"5","author":"Cubeddu","year":"2009","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.ihj.2013.12.021_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0195-668X(02)00806-0","article-title":"Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome\u2013a case-control pilot study using i.v. sotalol","volume":"24","author":"Kaab","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2013.12.021_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jacc.2005.08.066","article-title":"T-wave alternans and the susceptibility to ventricular arrhythmias","volume":"47","author":"Narayan","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib20","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/hc0602.103724","article-title":"Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes","volume":"105","author":"Gbadebo","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.021_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1388-9842(01)00235-5","article-title":"Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure","volume":"4","author":"Brendorp","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ihj.2013.12.021_bib22","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJM199909163411201","article-title":"Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group","volume":"341","author":"Torp-Pedersen","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.12.021_bib23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/00002018-200124080-00002","article-title":"Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome","volume":"24","author":"Drici","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.ihj.2013.12.021_bib24","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1161\/01.CIR.97.22.2237","article-title":"Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the\u00a0International LQTS Registry","volume":"97","author":"Locati","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.021_bib25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0002-8703(99)70029-3","article-title":"Effect of dofetilide on survival in patients with supraventricular arrhythmias","volume":"138","author":"Pritchett","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.ihj.2013.12.021_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/107424840501000307","article-title":"Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale","volume":"10","author":"Nagra","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ihj.2013.12.021_bib27","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/01.CIR.102.19.2385","article-title":"Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study","volume":"102","author":"Singh","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.021_bib28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1517\/14656566.4.6.973","article-title":"Dofetilide: a new drug to control cardiac arrhythmia","volume":"4","author":"Elming","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ihj.2013.12.021_bib29","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/europace\/eup293","article-title":"Dofetilide is safe and effective in preventing atrial fibrillation recurrences in patients accepted for catheter ablation","volume":"11","author":"Shamiss","year":"2009","journal-title":"Europace"},{"key":"10.1016\/j.ihj.2013.12.021_bib30","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1592\/phco.20.9.776.35208","article-title":"Dofetilide, a new class III antiarrhythmic agent","volume":"20","author":"Lenz","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ihj.2013.12.021_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1542-474X.2006.00098.x","article-title":"An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence","volume":"11","author":"McBride","year":"2006","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib32","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.jacc.2006.07.010","volume":"48","author":"Zipes","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1540-8167.1995.tb00445.x","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias","volume":"6","author":"Echt","year":"1995","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-5273(96)02856-2","article-title":"Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group","volume":"58","author":"Frost","year":"1997","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib35","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1540-8159.2005.00179.x","article-title":"A typical proarrhythmia with dofetilide: monomorphic VT and exercise-induced torsade de pointes","volume":"28","author":"Reiffel","year":"2005","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib36","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1161\/01.CIR.102.21.2665","article-title":"Cardiovascular drugs. Dofetilide","volume":"102","author":"Mounsey","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.021_bib37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1542-474X.2007.00161.x","article-title":"Dofetilide-induced long QT and torsades de pointes","volume":"12","author":"Aktas","year":"2007","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10840-008-9290-6","article-title":"Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter","volume":"23","author":"Banchs","year":"2008","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib39","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1053\/euhj.1999.2039","article-title":"Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study","volume":"21","author":"Bianconi","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2013.12.021_bib40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/europace\/eup084","article-title":"Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation","volume":"11","author":"Coleman","year":"2009","journal-title":"Europace"},{"key":"10.1016\/j.ihj.2013.12.021_bib41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/01.CIR.104.3.292","article-title":"Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy","volume":"104","author":"Pedersen","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.021_bib42","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0735-1097(01)01106-8","article-title":"Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation","volume":"37","author":"Mazur","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib43","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1540-8159.2009.02479.x","article-title":"Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study","volume":"32","author":"Wells","year":"2009","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib44","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1046\/j.1540-8167.2003.90402.x","article-title":"Clinical experience with dofetilide in the treatment of patients with atrial fibrillation","volume":"14","author":"Prystowsky","year":"2003","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jacc.2010.07.047","article-title":"Efficacy and safety of dofetilide in the treatment of frequent ventricular tachyarrhythmias after amiodarone intolerance or failure","volume":"57","author":"Pinter","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib46","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1345\/aph.1D465","article-title":"Phase IV trial evaluating the effectiveness and safety of dofetilide","volume":"38","author":"Guanzon","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ihj.2013.12.021_bib47","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1540-8167.2011.02183.x","article-title":"Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies","volume":"23","author":"Baquero","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib48","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.yjmcc.2004.09.001","article-title":"Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes","volume":"37","author":"Sun","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ihj.2013.12.021_bib49","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1540-8159.2011.03245.x","article-title":"Coronary artery disease potentiates response to dofetilide for rhythm control of atrial fibrillation","volume":"35","author":"Manocha","year":"2012","journal-title":"Pacing Clin Electrophysiol"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483213003994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483213003994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:47:27Z","timestamp":1758080847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483213003994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0019483213003994"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2013.12.021","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dofetilide induced torsade de pointes: Mechanism, risk factors and management strategies","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2013.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Cardiological Society of India. Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}